Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immunome Inc.IMNM · Entity 4219 | CHIEF LEGAL OFFICER & GC | July 23, 2026 | July 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immunome Inc.
Report date July 23, 2026 · Filed July 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,805 |
Reported balance
After 2026-07-23 transaction · row 1
1 source rowRow 1 · 2026-07-23 · Grant · Acquired 38,250 · Balance 43,805 F1: Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.01 · Expires 2036-07-22 | Direct | 76,500 |
Reported balance
After 2026-07-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-23 · Grant · Acquired 76,500 · Balance 76,500 F2: 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
F2: 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 23, 2026 Filed Jul 27, 2026 20:10 UTC | Immunome Inc. IMNM · Entity 4219 | GrantEmployee Stock Option (right to buy) · Derivative | 76,500 | $0.00 Strike: $22.01 | $0.00 |
DisclosureSEC source: 0001831144-26-000002 · form4-07272026_040709.xml · derivative · entry 2 Stoneman Sandra G. · CIK 0001831144 · CHIEF LEGAL OFFICER & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,500 Underlying: Common Stock · 76,500 shares Expires 2036-07-22 F2 · derivative.exercise_date: 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 23, 2026 Filed Jul 27, 2026 20:10 UTC | Immunome Inc. IMNM · Entity 4219 | GrantCommon Stock | 38,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001831144-26-000002 · form4-07272026_040709.xml · nonDerivative · entry 1 Stoneman Sandra G. · CIK 0001831144 · CHIEF LEGAL OFFICER & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,805 F1 · shares: Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 29, 2025 Filed Jul 31, 2025 22:48 UTC | Immunome Inc. IMNM · Entity 4219 | GrantEmployee Stock Option (right to buy) · Derivative | 190,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001415889-25-020779 · form4-07312025_100744.xml · derivative · entry 1 Stoneman Sandra G. · CIK 0001831144 · CHIEF LEGAL OFFICER & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires 2035-07-28 F1 · derivative.exercise_date: 25% of the shares subject to the options vest on July 29, 2026, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 21:54 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock option (right to buy) · Derivative | 210,000 | $0.00 Strike: $12.92 | $0.00 |
DisclosureSEC source: 0001415889-24-021238 · form4-08132024_090806.xml · derivative · entry 1 Stoneman Sandra G. · CIK 0001831144 · CHIEF LEGAL OFFICER & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,000 Underlying: Common Stock · 210,000 shares Expires 2034-08-08 F1 · derivative.exercise_date: 25% of the shares subject to the options vest on August 9, 2025, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter. Read SEC document |
| January 31, 2024 Filed Feb 1, 2024 01:50 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock option (right to buy) · Derivative | 200,000 | $0.00 Strike: $16.57 | $0.00 |
DisclosureSEC source: 0001415889-24-002119 · form4-02012024_010238.xml · derivative · entry 1 Stoneman Sandra G. · CIK 0001831144 · CHIEF LEGAL OFFICER & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-01-30 F1 · derivative.exercise_date: 25% of the shares subject to the options vest on January 31, 2025, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 21:01 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock Option (Right to Buy) · Derivative | 56,000 | $0.00 Strike: $4.84 | $0.00 |
DisclosureSEC source: 0001104659-23-070415 · tm2318426-11_4seq1.xml · derivative · entry 1 Stoneman Sandra G. · CIK 0001831144 · General Counsel and CLO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 56,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: One-forty-eighth (1/48th) of the shares subject to such options shall vest monthly over forty-eight months after the grant date. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 22:07 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock Option (Right to Buy) · Derivative | 43,000 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001104659-22-073106 · tm2218674-11_4seq1.xml · derivative · entry 1 Stoneman Sandra G. · CIK 0001831144 · General Counsel and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Common Stock · 43,000 shares Expires 2032-06-16 F1 · derivative.exercise_date: With respect to the options to purchase 33,000 shares, 25% of the shares subject to such options vest on June 16, 2023, and one-thirty-sixth (1/36th) of the remaining shares subject to such options shall vest every month thereafter. With respect to the remaining options to purchase 10,000 shares, 50% of the shares subject to such options vest on June 16, 2023, and the remaining 50% of the shares subject to such options vest on June 16, 2024. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 23:19 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock Option (Right to Buy) · Derivative | 16,609 | $0.00 Strike: $20.92 | $0.00 |
DisclosureSEC source: 0001104659-21-075234 · tm2118079-8_4seq1.xml · derivative · entry 1 Stoneman Sandra G. · CIK 0001831144 · General Counsel and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,609 Underlying: Common Stock · 16,609 shares Expires 2031-05-28 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on May 28, 2022, and one-thirty-sixth (1/36th) of the remaining shares subject to the option shall vest every month thereafter. Read SEC document |
| November 03, 2020 Filed Nov 6, 2020 02:26 UTC | Immunome Inc. IMNM · Entity 4219 | GrantEmployee Stock Option (Right to Buy) · Derivative | 148,837 | $0.00 Strike: $11.38 | $0.00 |
DisclosureSEC source: 0001104659-20-122047 · a4.xml · derivative · entry 1 Stoneman Sandra G. · CIK 0001831144 · Chief Legal Officer & Gen Coun 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,837 Underlying: Common Stock · 148,837 shares Expires 2030-11-03 F1 · security: Twenty-five percent (25%) of the shares subject to the option shall vest on October 26, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter. F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on October 26, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.